Pastorus is developing improved oxytocin products with patent-protected formulation and delivery platforms.
Oxytocin itself has multiple, favorable, Phase IIa (early proof of concept) trials in autism, schizophrenia and substance abuse. Pastorus is preparing for Phase IIb (confirmatory proof of concept) trials in each of these disorders with its new oxytocin products. Government and academic institutions have expressed active interest in helping support these trials.
Further information is available under confidentiality.